StreetInsider.com News Articles

UBS Downgrades Acadia Pharmaceuticals (ACAD) to Neutral

Tue, 13 Oct 2026 07:50:12 -0400

UBS analyst Ashwani Verma downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral with a price target of $23.00 (from $49.00).

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $19.41 yesterday.

Acadia Pharmaceuticals (ACAD) PT Lowered to $36 at RBC Capital

Thu, 08 Oct 2026 08:26:23 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $36.00 (from $37.00) while maintaining a Outperform rating.

RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'

Mon, 05 Oct 2026 13:49:49 -0400

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and a $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD), following a joint stipulation filed by ACAD and generic drugmaker Zydus to dismiss all claims and counterclaims in their pimavanserin (Nuplazid) patent litigation without prejudice.

The dismissal was filed one month before a scheduled November 2 trial, after more than a year of litigation. Zydus had been seeking generic approval for a 34 mg pimavanserin tablet, a formulation distinct from the approved 34 mg capsule. Settlement terms were not disclosed.

Abrahams noted that ACAD still has an outstanding case with Aurobindo/MSN at the

RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'

Mon, 05 Oct 2026 13:49:49 -0400

Abrahams noted that ACAD still has an outstanding case with Aurobindo/MSN at the

RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'

Mon, 05 Oct 2026 13:49:49 -0400

Abrahams noted that ACAD still has an outstanding case with Aurobindo/MSN at the

RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'

Mon, 05 Oct 2026 13:49:49 -0400

Abrahams noted that ACAD still has an outstanding case with Aurobindo/MSN at the

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Mon, 28 Sep 2026 16:05:00 -0400

-- The allowance strengthens the intellectual property portfolio for trofinetide and extends protections in the U.S. from July 2036 to March 2041

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and Compositions for Treatment of Rett Syndrome.” The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrative steps.

The patent application covers weight-banded

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Mon, 28 Sep 2026 16:05:00 -0400

-- The allowance strengthens the intellectual property portfolio for trofinetide and extends protections in the U.S. from July 2036 to March 2041

The patent application covers weight-banded

Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at H.C. Wainwright

Mon, 28 Sep 2026 06:57:31 -0400

(Updated - September 28, 2026 6:57 AM EDT)

H.C. Wainwright analyst Andrew S. Fein lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $37.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Acadia shared topline results from the Phase 2 portion of the RADIANT program evaluating remlifanserin (ACP-204) in Alzheimer's disease psychosis. The trial narrowly missed its primary endpoint but hit its key secondary nominally, and the company is continuing both ongoing Phase 3 studies with amendments. Our key takeaways: (1) on SAPS-H+D at week 6, remlifanserin 60 mg produced a −12.6 change versus −10.4 for placebo, a

Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at H.C. Wainwright

Mon, 28 Sep 2026 06:57:31 -0400

(Updated - September 28, 2026 6:57 AM EDT)

H.C. Wainwright analyst Andrew S. Fein lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $37.00) while maintaining a Buy rating.

Increasing unusual option volume: GENI ACAD BUG XEL LESL GFL AKAM NKTR BURL QFIN

Fri, 25 Sep 2026 10:03:56 -0400

Increasing unusual option volume: GENI ACAD BUG XEL LESL GFL AKAM NKTR BURL QFIN

Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at Needham

Fri, 25 Sep 2026 07:06:51 -0400

(Updated - September 25, 2026 7:06 AM EDT)

Needham analyst Ami Fadia lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $35.00 (from $40.00) while maintaining a Buy rating.

The analyst commented: "We are updating our model to reflect the results from the RADIANT study, which failed to meet the PE for either dose, but demonstrated meaningful results in a post hoc analysis in a subgroup of ~80% of patients with higher baseline severity. Based on the data, mgt plans to drop the 30mg dose, refine the inclusion criteria for the 60mg dose, revisit the powering assumptions for Ph 3 and

Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at Needham

Fri, 25 Sep 2026 07:06:51 -0400

(Updated - September 25, 2026 7:06 AM EDT)

Needham analyst Ami Fadia lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $35.00 (from $40.00) while maintaining a Buy rating.

Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citizens on Ph2 Miss for Remlifanserin

Fri, 25 Sep 2026 04:11:30 -0400

Citizens analyst Jason Butler lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $36.00) while maintaining a Market Outperform rating.

The analyst commented, "Phase 2 remlifanserin results show a near miss but leave reasons for sustained optimism in ongoing Phase 3 program; we reiterate our Market Outperform rating on Acadia Pharmaceuticals while we lower our risk-adjusted, DCF-derived price target to $33 from $36. This morning, Acadia reported top-line results from the RADIANT Phase 2 trial evaluating remlifanserin in Alzheimer's disease psychosis. The trial narrowly missed its primary endpoint in patients receiving the higher dose of remlifanserin, while achieving

Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citizens on Ph2 Miss for Remlifanserin

Fri, 25 Sep 2026 04:11:30 -0400

Citizens analyst Jason Butler lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $36.00) while maintaining a Market Outperform rating.

Form 8-K ACADIA PHARMACEUTICALS For: Sep 24

Thu, 24 Sep 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260924/27102890.html

Goldman Sachs Reiterates Sell Rating on Acadia Pharmaceuticals (ACAD)

Thu, 24 Sep 2026 13:41:34 -0400

Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $17.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst comments "ACAD's Phase 2 study of 5-HT2A inverse agonist remlifanserin in Alzheimer's disease psychosis (ADP) missed the primary endpoint of SAPS-H&D (scale for the assessment of positive symptoms - hallucinations and delusions) at 6 weeks (effect size 0.26; p=0.0603) - the study was powered at 80% for an effect size of 0.4. Despite the miss, ACAD plans to continue the Phase 3 program based on nominal significance on the secondary endpoint of clinical global impression-severity (CGI-S-ADP), numerical improvement in the exploratory

Goldman Sachs Reiterates Sell Rating on Acadia Pharmaceuticals (ACAD)

Thu, 24 Sep 2026 13:41:34 -0400

Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $17.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Thu, 24 Sep 2026 12:20:06 -0400

TD Cowen analyst Ritu Baral reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst comments "Remlifanserin Ph2 ADP data just missed stat sig on the 1o EP of SAPS H+D (p=0.06) but nominal sig on key 2o EP of CGI-S-ADP (p=0.008). ESs were 0.33 and 0.43, respectively, in a prespecified 60mg pt subgroup with higher BL psychosis. Safety was solid. Ph3 enrollment continues; ACAD will remove the 30mg arm and likely enrich for pts with even higher baseline psychosis pending FDA alignment. Our Take: While investor conviction into the Ph2 RADIANT data was middling, we

TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Thu, 24 Sep 2026 12:20:06 -0400

TD Cowen analyst Ritu Baral reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

Citi cuts Acadia Pharmaceuticals price target to $33

Thu, 24 Sep 2026 12:18:07 -0400

Citi analyst Yigel Nochomovitz lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 from $40.00, while maintaining a Buy rating, according to a research note.

The adjustment follows a reduction in the analyst's probability of success estimate for remlifanserin, lowered from 35% to 20% after a Phase 2 agitation in dementia with Parkinson's disease (ADP) readout.

Nochomovitz noted positives from the trial data, including a narrow miss in a difficult, high-placebo-response indication, evidence of dose response, and increasing separation from placebo through Week 6. The analyst also cited a statistically significant signal on the secondary CGI-S-ADP endpoint and no new

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.

The analyst comments "RADIANT miss is a near-term headwind to ACAD shares, but future development remains promising. Clear dose response, consistency of SAPS-H+D improvements over time, and stronger efficacy in higher psychosis burden patients all suggest remlifanserin is therapeutically active in ADP. While we are reducing our target to $34/share on incrementally lower PoS (35% vs. 40% prior), investors should not discount the potential for remlifanserin to show success in both ADP and LBDP. Acadia's strong commercial portfolio remains

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.